Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LNTH with free AI briefings, catalyst countdowns, and dilution alerts.

LNTH · Lantheus Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$683.6M Cash on Hand
CF+ Cash Runway
Follow LNTH by email Get an email when LNTH reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LNTH, unsubscribe in one click. Privacy

📣 What LNTH Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Perflutren
FDA approved Jul 2001 · Definity
Coronary Artery Disease Phase 4 · NCT00162370 Completed
Florbetaben (18F)
FDA approved Mar 2014 · Neuraceq
Cardiac Amyloidosis Phase 3 · NCT05184088 Completed
Florbetaben F 18 Alzheimer's Disease (AD) Phase 4 · NCT02681172 Completed
Fluorine F 18 Flurpiridaz Coronary Artery Disease Phase 3 · NCT01347710 Completed
[18F]PI-2620 Alzheimer Disease Phase 3 · NCT05641688 Recruiting
[68Ga]-LNTH-2401 Prostate Cancer Phase 2/3 · NCT07831824 Recruiting
99mTechnicium (sestamibi or tetrofosmin) Coronary Artery Disease Phase 3 · NCT01347710 Completed
Lutetium Lu 177-DOTA-DUNP19 LNTH2403 Relapsed / Refractory Osteosarcoma Phase 1/2 · NCT07357519 Recruiting
Sulfur hexafluoride lipid microspheres Von-Hippel Lindau Phase 2 · NCT03907657 Completed
Phase 2; LNTH2403 a single agent recommended… Relapsed / Refractory Osteosarcoma Phase 1/2 · NCT07357519 Recruiting
Lutetium Lu 177 Zadavotide Guraxetan Metastatic Renal Cell Carcinoma Phase 1/2 · NCT06361810 Withdrawn
Androgen Receptor Pathway Inhibitor Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Phase 2 · NCT07645326 Not yet recruiting
Fluorine F 18 Piflufolastat Prostate Cancer Diagnosis Phase 2 · NCT05820724 Unknown
Androgen Deprivation Therapy (ADT) Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Phase 2 · NCT07645326 Not yet recruiting
LMI 1195-101 Heart Failure Phase 1 · NCT00891241 Completed
Fludeoxyglucose (18F)-IBA Diagnostic Imaging Phase 1 · NCT01089998 Completed

Also used in these trials (approved or third-party drugs, not LNTH's own candidates): Piflufolastat F-18, Pembrolizumab, Docetaxel Anhydrous.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LNTH holds $683.6M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LNTH files for a raise →

👥 Who Owns LNTH

Insiders 42.2% Other 5%+ holders 57.8% Institutions (572 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Lantheus Omega, LLC 5%+ holder (13G) 792,958,513 1,212.45% 2026-07-28
Lantheus Holdings, Inc.
10% owner
Insider 11,563,425 17.68% 2026-09-01
Lantheus Alpha Therapy, LLC
10% owner
Insider 11,273,364 17.24% 2026-09-03
Dapice Joshua J. 5%+ holder (13G) 5,427,479 8.30% 2025-12-31
Pentwater Capital Management LP Institution (13G, 5%+) 3,900,000 5.96% 2026-09-30
FARALLON PARTNERS L L C/CA
10% owner
Insider 3,477,227 5.32% 2025-08-19
Rajiv A Patel
Member of a Group Owning 10%
Includes shares also reported by FARALLON PARTNERS L L C/CA, counted once
Insider 3,477,227 5.32% 2025-08-19
Vanguard Capital Management Institution (13G, 5%+) 3,421,414 5.23% 2026-03-31
Mary Anne Heino
Executive Chair and CEO, Director · +26,325 options
Insider 587,968 0.90% 2026-05-14
Robert J. Jr. Marshall
CFO and Treasurer
Insider 122,071 0.19% 2026-08-31
Daniel Niedzwiecki
Chief Administrative Officer, General Co
Insider 117,465 0.18% 2026-04-17
Paul Blanchfield
President
Insider 108,214 0.17% 2025-08-13

Share count 65,401,413 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-03-06 PYLARIFY TruVu NDA +15.6% -4.9% +5.4%

Browse all historical PDUFA outcomes →

Get the full LNTH picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LNTH and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.